Zydus Lifesciences: Motilal Oswal Raises Target Amid Growth Concerns

Motilal Oswal has increased its earnings projections for Zydus Lifesciences for fiscal years 2027 and 2028. This revision stems from strong performance in U.S. products, particularly those with limited competition, and better-than-market results in the domestic formulations business. The brokerage also factored in enhanced research and development (R&D) and marketing initiatives as key growth drivers.

Valuing Future Growth

Motilal Oswal has established a new target price of Rs 1,080 for Zydus Lifesciences. This target is based on a forward earnings multiple of 21 times for the next 12 months, projecting an estimated 7% earnings compound annual growth rate (CAGR) from FY26 to FY28. The brokerage increased its earnings estimates by 5% for FY27 and 4% for FY28, reflecting confidence in the company's future growth. However, a Neutral rating is maintained because the current stock valuation is seen as offering limited potential for significant gains.

Competitive Strengths and Market Trends

Zydus Lifesciences operates within a competitive pharmaceutical landscape, facing major players such as Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, and Cipla. The Indian pharmaceutical market is expected to grow at about 11.26% annually between 2025 and 2035, fueled by domestic demand and exports. Zydus aims to expand its U.S. specialty portfolio through various strategies, including acquisitions and licensing, while also diversifying into medical devices, diagnostics, and nutrition. The U.S. generics market remains a focus, with plans for exclusive product launches. Growth in the U.S. formulations business is attributed to new product introductions and traction in its specialty offerings. The domestic business has outpaced the market, boosted by new products and strong performance in key therapy areas. Significant R&D spending is directed towards developing complex products like injectables, biosimilars, and vaccines for long-term expansion.

Potential Challenges: Valuation and Margins

Despite a positive outlook, potential risks exist. Analysts suggest Zydus Lifesciences' current valuation might be overstretched. Some analyses indicate the stock could be overvalued by 25% compared to its intrinsic value. Although the company reported strong Q4 FY26 results with record sales and margins, concerns persist about future U.S. sales due to increasing competition and potential price declines. High R&D investments, essential for future growth, also add to costs. The Indian pharmaceutical sector generally faces challenges like price erosion in the U.S. and regulatory pressures.

Outlook and Projections

Motilal Oswal forecasts a 7% earnings CAGR for Zydus Lifesciences from FY26 to FY28. The company is expected to achieve high single-digit growth in North America and outperform the Indian market by 200 to 400 basis points in FY27. International markets are anticipated to maintain their strong growth momentum, with the consumer segment expected to see double-digit growth. Margins are projected to stay above 24%, assuming an 8% R&D expense.